Promomed developed the drug Quincenta containing semaglutide
Clinical trial objectives The purpose of the clinical study in humans was to evaluate the efficacy of four weeks supplementation of a combination of vitamin B6, B9, B12, and taurine on motivated behavior, as a primary outcome, and on attentional performance, and self-reported mood (e.g., fatigue, vigor) as secondary outcomes
Manufacturer guidance explicitly recommends avoiding use during lactation
[14] [15] In contrast, tirzepatide is not a diuretic and does not directly act on renal tubules to promote fluid excretion
The key concerns with compounded semaglutide are: Incorrect dosing from unregulated suppliers Improper formulation (e.g., using semaglutide salts instead of base) Contamination in non-sterile labs Always confirm your provider: Uses licensed 503A/503B U.S